Related Experiment Video

Updated: Jun 5, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Treatment-related myelodysplastic syndrome: molecular characteristics and therapy

Ravi Bhatia1, H Joachim Deeg

  • 1Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA. rbhatia@coh.org

Current Opinion in Hematology
|January 22, 2011
PubMed
Abstract

Insights

Identifying genetic risk factors for treatment-related myelodysplastic syndrome (t-MDS) aids in early detection and prevention. Advances in understanding t-MDS pathogenesis and hematopoietic cell transplantation outcomes are improving patient care.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Treatment-related myelodysplastic syndrome (t-MDS) is a severe complication following cancer therapy.
  • Understanding t-MDS is crucial for improving patient outcomes after cancer treatment.

Purpose of the Study:

  • To review recent advances in the risk factors, pathogenesis, and treatment of t-MDS.
  • To highlight the significance of genetic predispositions in t-MDS development.

Main Methods:

  • Review of recent scientific literature on t-MDS.
  • Analysis of genetic risk factors and their role in pathogenesis.
  • Evaluation of outcomes for hematopoietic cell transplantation in t-MDS patients.

Main Results:

  • New insights into genetic factors predisposing individuals to t-MDS after cytotoxic therapy.
  • Investigation into the role of specific genes in t-MDS pathogenesis.
  • Elucidation of factors influencing outcomes of hematopoietic cell transplantation for t-MDS.

Conclusions:

  • Improved understanding of genetic risk factors enables early identification of at-risk patients.
  • This knowledge supports informed therapeutic decisions and timely interventions.
  • Hematopoietic cell transplantation offers curative potential, but further improvements are needed.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...